What is the clinical evidence from this study?

Study design: RCT. Population: Hypertension (n=38). Intervention: Terazosin vs. Placebo. Primary outcome: Average blood pressure reduction.

What does this research mean for the field?

Once-daily terazosin (10 mg) lowers supine blood pressure from baseline with peak efficacy occurring 1 to 3 hours post-dose, but blood pressure reductions do not significantly differ from placebo at the end of the 24-hour dosing interval. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

September 10, 1985Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy

Antihypertensive Therapy with Once‐daily Administration of Terazosin, a New Alpha1‐adrenergic‐receptor Blocker

View Full Paper

Ask AI

Bookmark

Key result

Terazosin fails to reduce blood pressure compared to placebo.

n=38

Why the study?

The antihypertensive activity and effect on blood lipids of terazosin, a new alpha1-adrenergic-receptor blocker, were compared with placebo in hypertension patients.

Does terazosin 10 mg once daily reduce blood pressure compared to placebo in patients with hypertension?

Comparison

Terazosin 10 mg once daily vs placebo

Design

Double-blind randomized controlled trial

Authors

PAPaul A. AbrahamHospices Civils de Lyon CHCharles E. HalstensonProteogenomics Research Institute for Systems Medicine GMGary R. MatzkeUniversity of North Carolina at Chapel Hill

Discussion

Member takes

Implication

Terazosin 10 mg daily fails to outperform placebo for supine BP reduction; challenges its antihypertensive efficacy and leaves open optimal dosing or timing.

Study Design

Type

RCT (n=38)

Blinding

Double-blind

Randomization

randomized

Structured PICO

Does terazosin 10 mg once daily reduce blood pressure compared to placebo in patients with hypertension?

Population

38 patients with hypertension randomized to receive terazosin or placebo for 4 weeks of maintenance therapy.

Intervention

Terazosin titrated over 2 weeks to a maintenance dosage of 10 mg once daily for 4 weeks.

Comparator

Placebo (following a 3-week placebo baseline period).

Outcome

Antihypertensive efficacy (blood pressure) assessed at the end of the 24-hour dosing interval and for 3 hours after drug ingestion.surrogate

Terazosin 10 mg once daily demonstrated greater antihypertensive activity 1-3 hours after ingestion than at the end of the 24-hour dosing interval, but did not significantly reduce supine blood pressure compared to placebo.

Cite This Study

Abraham et al. (1985) conducted an RCT in Hypertension (n=38). Terazosin vs. Placebo was evaluated on Average blood pressure reduction. Terazosin 10 mg once daily reduced supine blood pressure from baseline, but the reductions did not differ significantly from the placebo response.

synapsesocial.com/papers/6ab5e23c6d2c024023862df9 https://doi.org/10.1002/j.1875-9114.1985.tb03429.x

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Implication

Terazosin 10 mg daily fails to outperform placebo for supine BP reduction; challenges its antihypertensive efficacy and leaves open optimal dosing or timing.

Antihypertensive Therapy with Once‐daily Administration of Terazosin, a New Alpha1‐adrenergic‐receptor Blocker

Discussion

Member takes

Implication

Study Design

Structured PICO

Cite This Study

Topics

Antihypertensive Therapy with Once‐daily Administration of Terazosin, a New Alpha1‐adrenergic‐receptor Blocker

Discussion

Member takes

Implication

Study Design

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider